Free to access research in a post-MiFID2 world
MDxHealth (MDXH-BR): Growth in prospect a compelling opportunity
Recommendation: OUTPERFORM (from Under Review)
Target Price EUR9.00 (from Under Review)
Current Price (as at cob 26th February 2018): EUR3.43
Disappointment especially in H2/2017 hit the shares. MDxHealth's potential in prostate cancer diagnosis remains intact; creating a significant opportunity for investors. Test volumes of marketed diagnostics are growing and should accelerate with a fully installed US salesforce and expanding European distribution network. Broadening US reimbursement and product coding should see ConfirmMDx volumes translate into revenues as payment collection accelerates. Data expected during 2018 supporting the use SelectMDx in both primary diagnosis and patient monitoring should highlight the potential of this powerful prostate diagnostic and drive adoption in key clinical guidelines. With this growth and catalysts in prospect, we reinstate our OUTPERFORM recommendation (from Under Review) with a new target price of EUR9.
ConfirmMDx turning volume into revenue - Although disappointing on the topline, ConfirmMDx test volumes picked up in Q4 suggesting the expanded tasked and targeted salesforce is now having an impact. We anticipate increased adoption by physicians as private health providers such as Kaiser and other health groups implement the test into their clinical protocols. Only a little more than 50% of tests billed are currently booked. This should increase substantially as the CPT (Current Procedural Terminology) code applied in January begins to facilitate and speed test reimbursement. This will significantly improve test margins with a positive impact both on revenues and net cash flows. The company also expects to add significantly to the 67 signed up payers further extending access to the 1m men that are referred for biopsy every year.
SelectMDx a major opportunity - A lower price more convenient urine test, SelectMDx is showing growing potential early prostate cancer diagnosis of the around 10m men with elevated PSA. Data from studies currently under analysis is expected to highlight the utility of the test in disease monitoring and support the adoption of the tests into the key US and European clinical guidelines. Use in monitoring of men with slow growing or potentially indolent disease could at least double the addressable market.
MRI not fit for purpose - While a valuable and important tool for tumour visualisation, its inherent variability makes much hyped MRI unsuited to much needed large scale accurate prostate cancer diagnosis and stratification. Scalable and reproducible Confirm- and SelectMDx promise an accurate and cost-effective solution to fill this need.
A substantial opportunity at current levels - Despite uncertainty over exact timing, we are confident that accelerating volume growth will translate into substantial revenue growth in 2018 and 2019. With data supporting the increasing opportunity for the SelectMDx liquid biopsy, this should drive the share price over the next 12 months and longer term. Our estimates suggest a fair value of EUR6.50 rising towards EUR12 with data supporting wider use of SelectMDx. A fund-raising, in our view, is an outstanding opportunity for investors.
goetzpartners Corporate Research | Research Team
Dr. Chris Redhead | Analyst
goetzpartners Corporate Research
goetzpartners securities Limited
The Stanley Building, 7 Pancras Square, London, N1C 4AG, England, UK.
T +44 (0) 203 859 7725 | email@example.com / firstname.lastname@example.org
Registered in England No. 04684144.
Managing Directors: Dr Stephan Goetz, Martin Brunninger and Ulrich Kinzel.
To be added, or to change your subscriptions or to be removed / unsubscribed entirely from our CRM, please e-mail: ResearchProduction@goetzpartners.com
This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.
This communication (including any links and or attachments) from goetzpartners securities Limited ("GPSL") is confidential and may contain information which is proprietary, privileged or otherwise legally protected against unauthorised use or disclosure. If you receive this communication in error or are not the intended recipient of this communication, please delete and destroy all copies in your possession, notify the sender that you have received this communication, and note that any review or dissemination of, or the taking of any action in reliance on this communication is expressly prohibited. GPSL shall not be liable for the improper or incomplete transmission of the information contained in this communication nor for any delay in its receipt or damage to your system. GPSL does not guarantee that the integrity of this communication has been maintained nor that this communication is free of viruses, interceptions or interference and makes no warranties in relation to these matters. This is not an offer or a solicitation to buy or sell securities or investment products, or an official confirmation. GPSL record electronic and phone communications in accordance with FCA and MiFID2 regulations, they will be monitored for regulatory and training purposes. GPSL is authorised and regulated by the Financial Conduct Authority of the United Kingdom (Firm Reference Number: 225563).
About GPSL: goetzpartners securities Limited is a member of the goetzpartners group and a leading true pan European investment bank and research firm. We bring together a wide range of expertise, insights and innovations to advance the interests of our clients around the world. The fast changing environment brings challenges for businesses and investors. Research innovation, digital transformation and disruptive business ideas reshuffle the corporate world in a yet unexperienced pace. Our sector knowledge and our global footprint bring together deep understanding of the industry, corporate intelligence and a wide network of top decision makers.
GPSL publishes and distributes "Investment" Research and "Corporate Sponsored" Research. Our Corporate Sponsored Research is free to access and is not classified as an inducement in a post-MiFID2 world. GPSL does not offer any execution or market making services.
Click on the following link for the GPSL MiFID2 Investor Guidance Notice
GPSL equity research publications are also available and accessible on the following aggregators (for Institutional Use Only): AlphaSense, Bloomberg (GOET), Capital IQ, EQS, FACTSET, RNS Reach and Thomson Reuters.
If you cannot click on the above hyperlink please copy the below link and paste it into your browser for the full pdf version of the equity research report:
Dissemination of a FINANCIAL NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.